Brooks Automation, Inc. Fiscal 2015 Form 10-K Summary
Filing identity: The source filing identifies the registrant as Brooks Automation, Inc. for the fiscal year ended September 30, 2015. It does not identify the company as Azenta, Inc.; investors should verify the requested company and filing identity. Fiscal fourth-quarter results are included within the annual filing.
Business Context and Reporting Period
Brooks provided automation, cryogenic, semiconductor capital-equipment, and life-science biological sample-management solutions through three reportable segments: Brooks Product Solutions, Brooks Global Services, and Brooks Life Science Systems. Approximately 63% of fiscal 2015 revenue originated outside North America. The company had 1,426 full-time employees at September 30, 2015.
Fiscal 2015 included the October 2014 acquisition of FluidX and the August 2015 acquisition of Contact. The Granville-Phillips business was sold in May 2014 and is presented as a discontinued operation in prior-period results.
Key Financial Metrics
| Metric | Fiscal 2015 | Fiscal 2014 | Change |
|---|---|---|---|
| Revenue | $552.7 million | $482.8 million | +14.5% |
| Gross profit | $189.1 million | $167.3 million | +13.0% |
| Gross margin | 34.2% | 34.7% | -0.5 percentage points |
| Operating income | $16.9 million | $(2.7) million | Improved by $19.6 million |
| Operating margin | 3.1% | (0.6)% | Improved |
| Net income attributable to Brooks | $14.2 million | $31.4 million | -54.7% |
| Diluted EPS | $0.21 | $0.46 | Declined |
| Operating cash flow | $43.7 million | $53.8 million | Declined by $10.1 million |
Fiscal 2015 product revenue was $457.4 million and service revenue was $95.3 million. Segment revenue was $390.1 million for Product Solutions, $94.5 million for Global Services, and $68.1 million for Life Science Systems. Life Science Systems generated a segment operating loss of $19.6 million, compared with a $8.4 million loss in fiscal 2014.
Fourth-quarter fiscal 2015 revenue was $145.8 million, gross profit was $52.8 million, operating income was $10.1 million, net income was $6.6 million, and diluted EPS was $0.10.
Liquidity, Debt, and Capital Resources
- Cash and cash equivalents were $80.7 million; marketable securities totaled $133.3 million, for combined liquidity of $214.0 million.
- Working capital was $105.6 million.
- The $7.8 million capital lease obligation was extinguished when the company purchased its Chelmsford building and related land for $8.4 million on September 30, 2015. No capital lease obligations remained at year-end, and the filing does not report other material borrowings.
- Fiscal 2015 investing cash uses included $16.1 million of capital expenditures, $14.5 million for acquisitions, and $5.5 million for investments, partially offset by $16.7 million of marketable-security proceeds.
- Cash dividends paid were $27.0 million, or $0.40 per share declared for fiscal 2015.
- A $50 million share-repurchase authorization was approved on September 29, 2015, but no shares were repurchased under the program during fiscal 2015.
Material Changes Versus the Prior Comparable Period
- Revenue increased $69.9 million, driven primarily by Product Solutions growth and contributions from DMS and FluidX; reported growth included a $9.4 million adverse foreign-exchange effect.
- Product Solutions revenue increased 19.8% to $390.1 million, including $44.0 million from DMS and 8.1% organic growth.
- Global Services revenue was essentially flat at $94.5 million, while Life Science Systems revenue increased 7.8% to $68.1 million, including $15.0 million from FluidX.
- Consolidated gross margin declined because of substantially lower Life Science Systems margins, which fell to 26.0% from 37.1%. Product Solutions and Global Services margins improved.
- Operating results returned to profitability, but fiscal 2014 net income benefited from $30.0 million of after-tax discontinued-operation income, including the Granville-Phillips sale gain. Fiscal 2015 had no discontinued-operation income.
- Restructuring charges declined to $4.7 million from $6.3 million and included workforce reductions of approximately 93 positions and facility-related costs.
- Cash from operations declined despite higher earnings, primarily because of increased accounts receivable and inventory and lower deferred revenue.
- The Yaskawa Brooks Automation joint venture was dissolved and liquidated during fiscal 2015, resulting in a $0.7 million investment impairment charge and $0.2 million of liquidation costs.
Outlook, Commentary, Risks, and Unusual Items
Management expected continued investment in semiconductor automation and life-science sample-management products, including Twin-bank and BioStore III Cryo systems. The filing does not provide formal fiscal 2016 revenue or earnings guidance. Management stated that it had adequate resources for planned working capital and capital expenditures over the next twelve months, while noting that longer-term liquidity is difficult to predict because of market cyclicality.
- Semiconductor capital-equipment demand is cyclical and can produce significant fluctuations in revenue, margins, inventory, and operating results.
- Customer concentration remains material: the ten largest customers represented approximately 38% of fiscal 2015 revenue, and Applied Materials represented approximately 12%.
- Backlog declined to $107.8 million from $126.9 million; backlog scheduled within twelve months declined to $96.0 million from $113.6 million. Orders may be canceled or rescheduled without significant penalty.
- International exposure creates foreign-exchange, political, regulatory, trade, collection, and intellectual-property risks. A hypothetical 10% currency-rate change was estimated to affect net income by approximately $0.1 million.
- Goodwill and net intangible assets totaled $121.4 million and $55.4 million, respectively. No goodwill impairment was recorded, but impairment remains a risk if forecasts or business conditions deteriorate.
- Inventory was $100.6 million, with excess and obsolete inventory reserves of $23.8 million.
- Contractual commitments totaled $94.5 million, including $80.3 million of contractual cash obligations and $3.5 million of letters of credit. Non-cancelable inventory purchase commitments were $77.2 million.
- The company had $3.6 million of unrecognized tax benefits and related interest and a $1.0 million note receivable carried at fair value after a prior $2.6 million impairment.
- After year-end, the company agreed to acquire BioStorage Technologies for $127.0 million, subject to customary closing conditions and adjustments, with closing expected in the first quarter of fiscal 2016.
Most Important Facts for Investors to Verify
- Confirm whether the filing belongs to Brooks Automation rather than Azenta, Inc., as the supplied filing name and reporting company do not match the request metadata.
- Assess the sustainability of the return to operating profitability excluding acquisitions, restructuring benefits, discontinued operations, and other unusual items.
- Evaluate the Life Science Systems segment’s persistent operating loss and the effect of manufacturing consolidation and contract manufacturing on future margins.
- Review liquidity after the proposed $127.0 million BioStorage acquisition, ongoing dividends, potential share repurchases, and contractual commitments.
- Monitor semiconductor-cycle exposure, customer concentration, backlog conversion, foreign-exchange effects, and inventory levels.
- Review acquisition accounting, goodwill and intangible-asset sensitivity, contingent consideration, and the integration performance of FluidX, Contact, and subsequent acquisitions.
- Verify the treatment and timing of the BioStorage transaction, including financing, purchase-price adjustments, regulatory approvals, and post-closing results.